Latin America Cell and Gene Therapy Market Accelerates with AI Tech

Latin America Cell and Gene Therapy Market Size, Top Key Players with Growth and Trends

The Latin America cell and gene therapy market size recorded US$ 3.72 billion in 2024, set to grow to US$ 5.25 billion in 2025 and projected to hit nearly US$ 58 billion by 2034, with a CAGR of 31.61% throughout the forecast timeline.

The Latin America cell and gene therapy market is witnessing robust growth, driven by the increasing prevalence of chronic and genetic diseases, including cancer, rare disorders, and immunological conditions. Advances in biotechnology, gene-editing technologies, and regenerative medicine are accelerating the development of innovative therapies. Expanding clinical trial activity in countries like Brazil and Mexico, coupled with government support, investments, and strategic collaborations between pharmaceutical companies and research institutions, is fostering a favorable environment. Rising awareness and adoption of personalized medicine further enhance market potential across the region.

Key Takeaways

• Latin America cell and gene therapy sector pushed the market to USD 3.72 billion by 2024.
• Long-term projections show USD 58 billion valuation by 2034.
• Growth is expected at a steady CAGR of 31.61% in between 2025 to 2034.
• The global cell and gene therapy market is set to grow from USD 21.82 billion in 2024 to USD 187.44 billion by 2034 at a 24% CAGR.
• Brazil held a major revenue share of approximately 38% in the Latin America cell and gene therapy market in 2024.
• Mexico is expected to witness the fastest growth during the predicted timeframe.
• By therapy type, the cell therapy segment registered its dominance over the global market with a share of approximately 58% in 2024.
• By therapy type, the gene therapy segment is expected to grow with the highest CAGR in the market during the studied years.
• By therapeutic area, the oncology segment held the largest revenue share of approximately 45% in the market in 2024.
• By therapeutic area, the rare genetic disorders segment is expected to show the fastest growth over the forecast period.
• By vector type, the viral vectors segment held a dominant presence in the Latin America cell and gene therapy market with a share of approximately 65% in 2024.
• By vector type, the non-viral delivery segment is expected to witness the fastest growth in the market over the forecast period.
• By cell source, the Autologous segment contributed the biggest revenue share of approximately 62% in the market in 2024.
• By cell source, the Allogeneic segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By manufacturing scale, the clinical-scale manufacturing segment held a dominant presence in the Latin America cell and gene therapy market with a share of approximately 60% in 2024.
• By manufacturing scale, the contract manufacturing & CDMO services segment is expected to witness the fastest growth in the market over the forecast period.
• By end user, the biopharma & biotechnology companies segment contributed the biggest revenue share of approximately 40% in the market in 2024.
• By end user, the hospitals & specialty clinics segment is expected to grow at the fastest CAGR in the market during the forecast period.

Executive Summary Table

What is meant by Cell and Gene Therapy?

The Latin America cell and gene therapy market is driving growth through rising prevalence of chronic and genetic diseases, expanding clinical trials, and increasing investments in biotechnology infrastructure. Cell and gene therapy refers to innovative medical treatments that modify or manipulate cells and genes to treat or cure diseases at their source. Cell therapy involves introducing live cells into a patient to repair or replace damaged tissues, while gene therapy targets defective genes to correct or regulate their function. These therapies are used in cancer, rare genetic disorders, and immunological conditions, offering personalized, long-term solutions and transforming conventional treatment paradigms.

Market Outlook

• Industry Growth Overview-The Latin America cell and gene therapy market is expanding rapidly, driven by rising genetic and chronic disease prevalence, advances in biotechnology, growing clinical trials, government support, and strategic collaborations, fostering innovation and wider adoption of personalized, regenerative therapies across the region.
• Regional Expansion -The market is expanding regionally, with Brazil and Mexico leading due to advanced clinical trial infrastructure, skilled healthcare professionals, and supportive regulatory frameworks. Other countries, including Argentina and Chile, are emerging markets, attracting investments and collaborations that promote broader adoption of innovative therapies across the region.
• Major Investors -The market is supported by key investors driving regional growth. Notable players include Brazil’s Bossa Invest, Eretz.bio, and GRIDS Capital, Chile’s The Ganesha Lab, and Argentina’s Cites, all funding innovative biotech ventures. These investors focus on early-stage companies and novel therapies, fostering the development of cell and gene therapies, advancing research, and expanding the market across Latin America.
• Startup Ecosystem -Latin America’s cell and gene therapy startup ecosystem is emerging fast. In Brazil, Celluris leads with CAR-T immunotherapies against hematological and solid tumors. Chile’s Cellus Medicina Regenerativa specializes in regenerative biotech, backed by government and science-venture programs. Also in Brazil, Terumo BCT is expanding automated manufacturing platforms across major Latin countries, facilitating scale and cost reduction. These startups and innovators leverage local expertise, regulatory openings, and grant-funded support to push clinical validation, exosome development, and personalized therapies toward broader access in the region.

Latin America Cell and Gene Therapy Market Trends

• Emphasis on Gene Therapy Starting Materials: Viral vectors remain dominant, but non-viral components, such as plasmid DNA, are growing rapidly in demand. In the market, there is a strong emphasis on starting materials essential for treatment development. Viral vectors remain the backbone for delivering genetic material; however, non-viral components, such as plasmid DNA, are gaining momentum.
• Increasing Investment in Third-Party Logistics (3PL) is a key driver for the market because these therapies require extremely sensitive transport, strict temperature control, and fast delivery. Enhanced 3PL infrastructure, particularly in cold chain, ultra-low temperature shipping, and real-time monitoring, reduces risk, product loss, and delays, enabling more clinical trials and commercial treatments across a broader geographical area. For instance, in 2024, Brazil’s 3PL segment saw strong growth, with cell therapy being the fastest-growing product type in Brazil’s pharmaceutical 3PL demand.
• Adopting Inorganic Growth Strategies, such as mergers, acquisitions, strategic partnerships, and licensing agreements, can significantly accelerate the Latin America cell and gene therapy market by enabling faster access to new technologies, expanding manufacturing capacity, and bridging regulatory or expertise gaps. 
• For instance,In October 2024, Terumo Blood & Cell Technologies expanded into Brazil, Colombia, and Mexico, enhancing its automated manufacturing platforms to support local cell and gene therapy developers. This kind of expansion reduces costs, improves supply chain efficiency, and accelerates product commercialization, helping therapies reach more patients across the region.

How Can AI Integration Improve the Market?

AI integration is revolutionizing cell and gene therapy by streamlining discovery, optimizing manufacturing, and enhancing clinical trial outcomes. Through predictive analytics, AI helps identify effective gene targets, improve viral vector design, and accelerate biomarker discovery for personalized treatments. In manufacturing, AI-powered automation reduces errors, increases scalability, and ensures quality control. Clinical trials benefit from AI-driven patient stratification and real-time monitoring, improving success rates and reducing costs. Companies like Novartis and Insilico Medicine are actively applying AI in developing advanced therapies, while Owkin leverages AI in precision oncology, demonstrating its transformative potential in making cell and gene therapies safer and more accessible.

Key Initiatives for the Cell and Gene Therapy Sector in Latin America

Segmental Insights

Which Therapy Type Segment Dominated the Latin America Cell and Gene Therapy Market?

The cell therapy segment dominates the market with a share of 58% due to rising demand for advanced treatments in oncology, regenerative medicine, and rare disorders. Strong clinical trial activity, especially in Brazil and Mexico, supports innovation, while increasing government initiatives and hospital partnerships enhance adoption. Additionally, growing regional expertise in CAR-T therapy and stem cell research strengthens its leadership in the market.

The gene therapy segment is estimated to be the fastest-growing segment in the Latin American cell and gene therapy market, with the gene editing sub-segment expanding rapidly due to breakthroughs in technologies such as CRISPR and adeno-associated viral vectors. These innovations enable precise genetic modifications, offering long-term solutions for rare diseases and cancers. Supportive regulations, growing clinical trials in Brazil and Mexico, and rising collaborations with global biotech firms are fueling momentum. Increasing investment in personalized medicine and heightened awareness of advanced therapies further position gene editing and gene therapy as the fastest-growing segment in the region’s healthcare innovation landscape.

Why Did the Oncology Segment Dominate the Latin America Cell and Gene Therapy Market?

The oncology segment dominates the market with a share of 45% due to the high prevalence of cancers and the urgent need for advanced treatments. Increasing adoption of CAR-T therapies, strong clinical trial activity in countries like Brazil and Mexico, and growing collaborations between hospitals, research institutions, and biotech companies support innovation. This focus on cancer therapies drives the segment’s leadership in the region.

The rare genetic disorders segment is estimated to be the fastest-growing segment in the Latin America cell and gene therapy market due to rising awareness of inherited diseases and the urgent need for targeted, personalized treatments. Advances in gene-editing technologies, such as CRISPR and viral vectors, enable precise interventions for these conditions. Increasing clinical trials, supportive regulatory frameworks in Brazil and Mexico, and strategic collaborations between biotech companies and research institutions are accelerating therapy development.

What Made Viral Vectors the Dominant Segment in the Latin America Cell and Gene Therapy Market?

The viral vectors segment dominates the market with a share of 65% due to their proven efficacy and versatility in delivering therapeutic genes. These vectors are widely used in CAR-T therapies, gene replacement, and immunotherapies, offering high safety and transduction efficiency. Strong clinical trial activity in Brazil, Mexico, and Chile, along with growing investments from biotech firms and research institutions, supports vector development, manufacturing, and adoption, solidifying AAV and lentivirus as the preferred platforms in the region’s advanced therapy landscape.

The non-viral delivery segment is anticipated to be the fastest-growing segment in the market due to its safety, scalability, and flexibility in delivering genetic material. These methods reduce immunogenicity and manufacturing complexity compared to viral vectors. Increasing research collaborations, rising clinical trials in Brazil and Mexico, and growing adoption of mRNA-based therapies and ex vivo gene editing are driving rapid expansion across the region.

Which Cell Source Segment Led the Latin America Cell and Gene Therapy Market?

The autologous segment dominates the market with a share of 62% due to its personalized approach, using a patient’s own cells to minimize immune rejection and enhance treatment safety. Widespread adoption in CAR-T therapies and regenerative medicine, strong clinical trial activity in Brazil and Mexico, and collaborations between hospitals, research institutions, and biotech companies further drive its preference. The segment’s reliability and effectiveness make it the leading cell source in the region.

The Allogeneic segment is estimated to be the fastest-growing segment in the market due to its “off-the-shelf” approach, enabling scalable production and quicker treatment delivery. Advances in immune-matching technologies, expanding clinical trials, and increasing adoption by biotech firms and hospitals are accelerating its use across oncology and regenerative therapies in the region.

Why Did the Clinical-Scale Manufacturing Segment Dominate the Latin America Cell and Gene Therapy Market?

The clinical-scale manufacturing segment dominates the market with a share of 60% due to the increasing number of early- and late-phase clinical trials requiring reliable, high-quality production. Investments in advanced bioprocessing facilities, automation, and quality control systems in countries like Brazil and Mexico support consistent output. Additionally, collaborations between biotech firms, hospitals, and contract development organizations enhance capacity, ensuring a timely supply of cell and gene therapies and strengthening the segment’s leadership in the region.

The contract manufacturing & CDMO services segment is anticipated to be the fastest-growing in the market due to rising demand for scalable, outsourced manufacturing solutions. These services enable biotech companies to accelerate commercialization, reduce costs, and ensure regulatory compliance. Investments in automated facilities, cold-chain logistics, and regional partnerships in Brazil, Mexico, and Chile are expanding capacity, supporting broader therapy adoption, and driving rapid growth in this segment.

What Made Biopharma & Biotechnology Companies the Dominant Segment in the Latin America Cell and Gene Therapy Market?

The biopharma & biotechnology companies segment dominates the market with a share of 40% due to their strong focus on research, development, and commercialization of advanced therapies. These companies lead in clinical trials, innovation in gene-editing and cell-processing technologies, and collaborations with hospitals and research institutions. Supportive regulatory frameworks in Brazil and Mexico, along with increasing investment in personalized medicine, further strengthen their ability to drive therapy development and maintain a dominant position in the regional market.

The hospitals & specialty clinics segment is estimated to be the fastest-growing segment in the Latin America cell and gene therapy market due to increasing adoption of advanced therapies for personalized and regenerative treatments. Their direct access to patients enables rapid clinical trial recruitment and real-world therapy application. Investments in specialized infrastructure, trained personnel, and partnerships with biotech companies enhance treatment delivery, while growing patient awareness and demand for innovative therapies accelerate market growth across Brazil, Mexico, and other key regional markets.

Regional Analysis

Which Factors Contribute to Brazil’s Dominance in the Latin America Cell and Gene Therapy Market?

Brazil dominates the Latin America cell and gene therapy market due to its advanced healthcare infrastructure, strong biotechnology research ecosystem, and high clinical trial activity. Supportive government policies, public funding for innovative therapies, and a growing network of hospitals and specialty clinics facilitate adoption. The country also attracts collaborations and investments from international biopharma companies, particularly in CAR-T and gene therapies.

How Big is the Opportunity for Mexico for Growth in the Market?

Mexico is the fastest-growing country in the market due to favorable regulatory reforms that facilitate clinical trials and therapy approvals. Expanding healthcare infrastructure, growing public and private investment, and rising collaborations between local biotech companies and international pharmaceutical firms accelerate research and commercialization. Additionally, increasing awareness of advanced therapies, adoption of personalized medicine, and development of specialized hospitals and clinics for cell and gene therapies further drive market expansion, positioning Mexico as a key hub for innovative treatments in the region.

Global Cell and Gene Therapy Market Growth

The global cell and gene therapy market is valued at USD 21.82 billion in 2024 and is projected to reach USD 187.44 billion by 2034, growing at a CAGR of 24% over the forecast period, driven by an increase in clinical trials and a rising number of product approvals.

Value Chain Analysis

Research & Development (R&D)

Target discovery, preclinical studies, vector design, cell processing, and formulation of therapy candidates.

Key Organizations:

• Brazil: Instituto Butantan, Fiocruz (Oswaldo Cruz Foundation), and Celluris – focus on CAR-T and stem cell therapies.
• Mexico: National Institute of Genomic Medicine (INMEGEN) – gene therapy research and early-stage development.
• Chile: Cellus Medicina Regenerativa – regenerative medicine and ex vivo cell therapy development.

Clinical Trials & Regulatory Approval

Phase I–III clinical trials, safety and efficacy testing, protocol approval, submission to regulatory agencies, and post-trial reporting.

Key Organizations / Regulators:

• Brazil: ANVISA (National Health Surveillance Agency) – oversees clinical trial approval and therapy registration. Hospitals and research centers in São Paulo and Rio de Janeiro host many trials.
• Mexico: COFEPRIS – manages trial approvals and therapy authorization. Collaboration with hospitals like the Instituto Nacional de Cancerología.
• Chile: ISP Chile (Institute of Public Health) – approves trials and therapy use in regenerative and gene therapy studies.

Patient Support & Services

Steps: Therapy administration, follow-up monitoring, patient education, logistics for therapy delivery (cold-chain management), and post-treatment care.

Key Organizations:

• Brazil: Hospitals such as Hospital Israelita Albert Einstein and Hospital das Clínicas provide CAR-T and stem cell therapy administration and patient support programs.
• Mexico: Specialty clinics and oncology centers like Centro Médico ABC and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán – patient counseling and therapy follow-up.
• Chile: Clinica Las Condes and Fundación Arturo López Pérez – focus on post-treatment care and patient education for gene and cell therapies.

Top Vendors in the Latin America Cell and Gene Therapy Market & Their Offerings:

Instituto Butantan (Brazil)

• Focus: Development of CAR-T cell therapies and other immunotherapies.
• Key Offerings: Advanced cell-based therapies for cancer treatment.
• Note: Collaborates with global institutions to enhance research and development in immunotherapy.

Fiocruz (Brazil)

• Focus: Research and development in gene therapy, particularly for infectious diseases.
• Key Offerings: Development of gene-based vaccines and therapies.
• Note: Plays a pivotal role in public health initiatives across Latin America.

Cellus Medicina Regenerativa (Chile)

• Focus: Regenerative medicine and stem cell therapies.
• Key Offerings: Stem cell-based treatments for various medical conditions.
• Note: Engages in clinical trials to validate the efficacy of regenerative therapies.

Instituto Nacional de Medicina Genómica (INMEGEN) (México)

• Focus: Genomic medicine and gene therapy research.
• Key Offerings: Genetic testing and development of gene therapies for hereditary diseases.
• Note: Collaborates with international research entities to advance genomic medicine.

Laboratório Pasteur (Brazil)

• Focus: Development of vaccines and gene therapies.
• Key Offerings: Gene-based vaccines targeting infectious diseases.
• Note: Part of the broader effort to enhance vaccine production capabilities in Latin America.

Laboratorio Elea (Argentina)

• Focus: Pharmaceutical development, including gene therapies.
• Key Offerings: Gene therapy products for various medical conditions.
• Note: Contributes to the expansion of gene therapy options in the Argentine market.

Biosonda Biotechnology (Chile)

• Focus: Biotechnology research and development.
• Key Offerings: Biotechnological solutions, including gene therapies.
• Note: Engages in the development of biotechnological products for medical applications.
• Nutera-RP: First CAR-T Cell Production Unit in Latin America

Top Companies in the Latin America Cell and Gene Therapy Market

• Novartis
• Roche / Spark Therapeutics (Roche group)
• Gilead Sciences (Kite Pharma)
• Pfizer Inc.
• AstraZeneca
• Sanofi
• Janssen (Johnson & Johnson)
• Takeda Pharmaceutical Company
• Merck & Co. (MSD)
• Moderna, Inc.
• Bluebird Bio
• Lonza Group (CMO/CDMO)
• Catalent, Inc. (CDMO)
• Thermo Fisher Scientific (manufacturing & analytics)
• Samsung Biologics
• Charles River Laboratories (CRO services)
• IQVIA / Parexel / ICON (regional CRO presence)
• Biomm S.A. (Brazil — regional biotech/manufacturing)
• Instituto Butantan (Brazil — vaccine & biologics manufacturing/research)
• Grupo Biotoscana / Regional Biotech & Hospital Networks

Recent Developments in the Latin America Cell and Gene Therapy Market

• In September 2025, Terumo BCT's Spectra Optia Apheresis System received regulatory approvals in 14 Latin American countries to treat rare and chronic diseases such as sickle cell disease, Guillain-Barré syndrome, and myasthenia gravis. This expansion enhances the availability of advanced therapeutic options for patients across the region.
• In October 2024, Terumo Blood and Cell Technologies expanded its automated manufacturing solutions across Brazil, Colombia, and Mexico. These solutions include the Quantum Flex Cell Expansion System and the FINIA Fill and Finish System, which are designed to streamline production processes, reduce costs, and increase accessibility to life-saving therapies in the region. 

Segments Covered in the Report

By Therapy Type

• Cell Therapy
• Stem Cell Therapy
• Immune Cell Therapy (CAR-T, TCR-T, NK cells, others)
• Cellular Vaccines & Others
• Gene Therapy
• Gene Augmentation / Replacement
• Gene Editing (CRISPR, TALENs, ZFNs)
• RNA-based Therapies (mRNA, siRNA, antisense)

By Therapeutic Area

• Oncology
• Rare Genetic Disorders
• Cardiovascular Diseases
• Neurological Disorders
• Ophthalmology
• Metabolic & Endocrine Disorders
• Infectious Diseases
• Others

By Vector / Delivery Type (for Gene Therapy)

• Viral Vectors
• AAV (Adeno-Associated Virus)
• Lentiviral Vectors
• Adenoviral & Retroviral Vectors
• Non-Viral Delivery
• Lipid Nanoparticles (LNPs)
• Electroporation / Physical Methods

By Cell Source (for Cell Therapy)

• Autologous
• Allogeneic

By Manufacturing Scale & Service

• Clinical-Scale Manufacturing (GMP for trials)
• Commercial-Scale Manufacturing
• Contract Manufacturing & CDMO Services
• Cell/Gene Analytics & Release Testing Services

By End User

• Hospitals & Specialty Clinics (centers offering advanced therapies)
• Biopharma & Biotechnology Companies
• Contract Research Organizations (CROs) & CMOs/CDMOs
• Academic & Research Institutes
• Government & Public Health Programs

By Country (Latin America)

• Brazil
• Mexico
• Argentina
• Chile
• Colombia
• Rest of Latin America